Membrane post treatment

Information

  • Patent Grant
  • 7867417
  • Patent Number
    7,867,417
  • Date Filed
    Friday, December 2, 2005
    18 years ago
  • Date Issued
    Tuesday, January 11, 2011
    13 years ago
Abstract
Hydrophilic porous polymeric membranes with high permeabilities, and processes for the preparation thereof are disclosed. Membranes may be prepared by including a preferably hydrophilic cross-linkable component such as PVP (either by inclusion into the polymer dope prior to casting, or coating or quenching cast membranes); and treating the polymeric microfiltration or ultrafiltration membrane with a crosslinking agent to cross-link said cross-linkable component. Preferred cross-linking agents include Fenton's reagent.
Description
TECHNICAL FIELD

The invention relates to the treatment of polymeric materials to enhance their chemical properties in ultrafiltration and microfiltration applications. In particular, the invention relates to the treatment of porous polymeric membranes to increase water permeability without loss of other desirable membrane characteristics.


BACKGROUND ART

The following discussion is not to be construed as an admission with regard to the state of the common general knowledge of those skilled in the art.


Synthetic polymeric membranes are well known in the field of ultrafiltration and microfiltration for a variety of applications including desalination, gas separation, filtration and dialysis. The properties of the membranes vary depending on the morphology of the membrane i.e. properties such as symmetry, pore shape, pore size and the chemical nature of the polymeric material used to form the membrane.


Different membranes can be used for specific separation processes, including microfiltration, ultrafiltration and reverse osmosis. Microfiltration and ultrafiltration are pressure driven processes and are distinguished by the size of the particle or molecule that the membrane is capable of retaining or passing. Microfiltration can remove very fine colloidal particles in the micrometer and submicrometer range. As a general rule, microfiltration can filter particles down to 0.05 μm, whereas ultrafiltration can retain particles as small as 0.01 μm and smaller. Reverse osmosis operates on an even smaller scale.


Microporous phase inversion membranes are particularly well suited to the application of removal of viruses and bacteria.


A large surface area is needed when a large filtrate flow is required. A commonly used technique to minimize the size of the apparatus used is to form a membrane in the shape of a hollow porous fibre. A large number of these hollow fibres (up to several thousand) are bundled together and housed in modules. The fibres act in parallel to filter a solution for purification, generally water, which flows in contact with the outer surface of all the fibres in the module. By applying pressure, the water is forced into the central channel, or lumen, of each of the fibres while the microcontaminants remain trapped outside the fibres. The filtered water collects inside the fibres and is drawn off through the ends.


The fibre module configuration is a highly desirable one as it enables the modules to achieve a very high surface area per unit volume.


In addition to the arrangement of fibres in a module, it is also necessary for the polymeric fibres themselves to possess the appropriate microstructure to allow microfiltration to occur.


Desirably, the microstructure of ultrafiltration and microfiltration membranes is asymmetric, that is, the pore size gradient across the membrane is not homogeneous, but rather varies in relation to the cross-sectional distance within the membrane. Hollow fibre membranes are preferably asymmetric membranes possessing tightly bunched small pores on one or both outer surfaces and larger more open pores towards the inside edge of the membrane wall.


This microstructure has been found to be advantageous as it provides a good balance between mechanical strength and filtration efficiency.


As well as the microstructure, the chemical properties of the membrane are also important. The hydrophilic or hydrophobic nature of a membrane is one such important property.


Hydrophobic surfaces are defined as “water hating” and hydrophilic surfaces as “water loving”. Many of the polymers used to cast porous membranes are hydrophobic polymers. Water can be forced through a hydrophobic membrane by use of sufficient pressure, but the pressure needed is very high (150-300 psi), and a membrane may be damaged at such pressures and generally does not become wetted evenly.


Hydrophobic microporous membranes are typically characterised by their excellent chemical resistance, biocompatibility, low swelling and good separation performance. Thus, when used in water filtration applications, hydrophobic membranes need to be hydrophilised or “wet out” to allow water permeation. Some hydrophilic materials are not suitable for microfiltration and ultrafiltration membranes that require mechanical strength and thermal stability since water molecules can play the role of plasticizers.


Currently, poly(tetrafluoroethylene) (PTFE), polyethylene (PE), polypropylene (PP) and poly(vinylidene fluoride) (PVDF) are the most popular and available hydrophobic membrane materials. However, the search continues for membrane materials which will provide better chemical stability and performance while retaining the desired physical properties required to allow the membranes to be formed and worked in an appropriate manner. In particular, it is desirable to render membranes more hydrophilic to allow for greater filtration performance.


Microporous synthetic membranes are particularly suitable for use in hollow fibres and are produced by phase inversion. In this process, at least one polymer is dissolved in an appropriate solvent and a suitable viscosity of the solution is achieved. The polymer solution can be cast as a film or hollow fibre, and then immersed in precipitation bath such as water. This causes separation of the homogeneous polymer solution into a solid polymer and liquid solvent phase. The precipitated polymer forms a porous structure containing a network of uniform pores. Production parameters that affect the membrane structure and properties include the polymer concentration, the precipitation media and temperature and the amount of solvent and non-solvent in the polymer solution. These factors can be varied to produce microporous membranes with a large range of pore sizes (from less than 0.1 to 20 μm), and possess a variety of chemical, thermal and mechanical properties.


Hollow fibre ultrafiltration and microfiltration membranes are generally produced by either diffusion induced phase separation (the DIPS process) or by thermally induced phase separation (the TIPS process).


The TIPS process is described in more detail in PCT AU94/00198 (WO 94/17204) AU 653528, the contents of which are incorporated herein by reference. The quickest procedure for forming a microporous system is thermal precipitation of a two component mixture, in which the solution is formed by dissolving a thermoplastic polymer in a solvent which will dissolve the polymer at an elevated temperature but will not do so at lower temperatures. Such a solvent is often called a latent solvent for the polymer. The solution is cooled and, at a specific temperature which depends upon the rate of cooling, phase separation occurs and the polymer rich phase separates from the solvent.


Microporous polymeric ultrafiltration and microfiltration membranes have been made from PVdF which incorporate a hydrophilising copolymer to render the membrane hydrophilic. While these copolymers do impart a degree of hydrophilicity to otherwise hydrophobic membranes, membranes formed from mixed polymers usually have a lower water permeability than equivalent hydrophobic PVdF membranes formed without copolymer. Further, in some cases, the hydrophilising components can be leached from the membrane over time.


Previous attempts to hydrophilise membranes formed from principally hydrophobic material have involved preparing hydrophobic membranes and subsequently coating these with a suitable hydrophilic material. More advanced forms of this process have involved attempts to chemically bond the hydrophilic coating to the hydrophobic membrane substrate by processes such as cross-linking. While these processes do lead to the introduction of a hydrophilic membrane in most cases, they suffer from the drawback that the resultant membranes often have reduced permeability. That is, previous attempts to hydrophilise membranes by crosslinking have led to reduced membrane permeabilities.


Additional attempts have involved the preparation of polymeric blends containing a hydrophilic reactable component, followed by reaction of the component subsequent to membrane formation. Again, these have resulted in porous polymeric membranes with some desired properties, however, such process result in porous polymeric membranes which are generally of low permeability


In the present case the inventors have sought to find a way to hydrophilise membranes made from normally hydrophobic polymer such PVdF to enhance the range of applications in which they may be used, while at the same time, retaining or improving upon the performance properties of the membrane, such the good intrinsic resistance of hydrophobic materials to chemical, physical and mechanical degradation and more particularly, to retain or enhance the water permeability of the membrane.


It is an object of the present invention to overcome or ameliorate at least one of the disadvantages of the prior art, or to provide a useful alternative, particularly in terms of methods of production.







DESCRIPTION OF THE INVENTION

In a first aspect, the invention provides a method of improving the permeability of porous polymeric membrane which includes a cross linkable component, said method including the step of treating said hydrophilic porous polymeric membrane with a cross linking agent.


Preferably, the porous polymeric membrane is a hydrophilic porous polymeric membrane. Preferably the cross linkable component is a hydrophilic cross linkable component.


As stated, prior art examples involving crosslinking of one or more membrane components typically have permeability going down when a cross-linkable component is used. Further, the methods of the prior art usually describe depositing a cross-linkable component onto the surface of the membrane and cross-linking it rather than having it incorporated into the dope mixture, where it is cast with the other membrane forming components into a membrane. The cross-linkable and non-crosslinkable components are preferably intimately mixed.


According to a second aspect, the invention provides a method of forming a hydrophilic polymeric microfiltration or ultrafiltration membrane including:

  • i) preparing a polymeric microfiltration or ultrafiltration membrane which contains a component which is cross-linkable; and
  • ii) treating said polymeric microfiltration or ultrafiltration membrane with a crosslinking agent to cross-link said cross-linkable component


Preferably, the polymeric microfiltration or ultrafiltration membrane also includes a hydrophobic and/or not crosslinkable component.


Preferably, the hydrophilic cross-linkable component is any hydrophilic cross linkable component capable of free radical cross linking. More preferably, the cross linkable component is capable of cross linking under oxidative conditions. Even more particularly preferred are components capable of crosslinking in the presence of hydroxyl radicals. Examples of suitable cross linkable components include monomers, oligomers, polymers and copolymers of one or more of the following: vinyl pyrrolidone, vinyl acetate, vinyl alcohol, vinyl methyl ether, vinyl ethyl ether, acrylic acid, methyl acrylate, ethyl acrylate, propyl acrylate, butyl acrylate, methyl methacrylate, ethyl methacrylate propyl methacrylate, butyl methacrylate and maleic anhydride.


Especially preferred are poly(vinyl pyrrolidone), poly(vinyl acetate) or copolymers of vinyl pyrrolidone and vinyl acetate.


The cross linkable component may be added at various stages in the preparation of the polymer, but are usually incorporated by addition into the polymer dope in membranes prior to casting. Alternatively, the cross linkable component may be added as a coating/lumen or quench during membrane formation. They may be added in any amount, from an amount constituting the whole of the membrane or substantially the whole of the membrane down to an amount which produces only a minimal attenuation of the hydrophilicity/hydrophobicity balance.


Preferably, the hydrophobic and/or non-cross linkable component is any polymer or copolymer of oxidation resistant material. Any polymer resistant to base attack containing one or more of the following monomers may be used: chlorotrifluoroethylene, vinyl fluoride, vinyl chloride; vinylidene fluoride/vinylidene chloride/; hexafluoropropylene, ethylene-chlorotrifluoroethlyene, tetrafluoroethylene. Particularly preferred as a non crosslinkable component is PVdF.


Chemical crosslinking is preferred. Particularly preferred as a method of cross linking is treating the polymeric ultrafiltration or microfiltration membrane with a hydroxyl radical. The hydroxyl radical may be prepared by any known source. The generation of hydroxyl radicals may, for example, be by way of an aqueous solution of Ferric chloride/hydrogen peroxide/sodium hydrogensulfate, by aqueous acidified hydrogen peroxide, by aqueous organic peroxy acids such as peracetic acid or by aqueous hydrogen peroxide under ultraviolet radiation, or by a combination of hydrogen peroxide and ozone, with or without UV radiation at any pH in the range 2-9.


Most preferred is treating the membranes with a solution of hydroxyl radicals prepared from an aqueous solution of transition metal catalyst in conjunction with hydrogen peroxide at a pH of 2-9, with or without UV radiation. Preferably the transition metal catalyst is a mixture of iron II/iron III.


The treatment may involve soaking, filtering or recirculating to cross-link the crosslinkable compound to the polymer matrix. UV light may be used if desired.


Preferably, after crosslinking, the process also includes a step of leaching unbound excess copolymer. The excess unbound copolymer can be washed out with water or any other suitable solvent, for a predetermined time or to a predetermined level of leachate. It is possible that some cross linked material will be washed out, ie some oligomeric and lower polymeric material not fully embedded in the matrix of non-crosslinkable and/or hydrophobic polymer.


According to a third aspect, the invention provides a method of functionalising a polymeric microfiltration or ultrafiltration membrane including:

  • i) preparing a polymeric microfiltration or ultrafiltration membrane which contains a component which is cross-linkable;
  • ii) treating said polymeric microfiltration or ultrafiltration membrane with a hydroxyl radical to cross-link said cross-linkable component; and
  • iii) leaching, where present, any unbound cross linked or unbound cross-linkable component.


According to a fourth aspect, the invention provides a method of increasing the permeability of a polymeric microfiltration or ultrafiltration membrane including:

  • i) preparing a polymeric microfiltration or ultrafiltration membrane which contains a component which is cross-linkable;
  • ii) treating said polymeric microfiltration or ultrafiltration membrane with a hydroxyl radical to cross-link said cross-linkable component; and
  • iii) leaching, where present, any unbound cross linked or unbound cross-linkable component.


According to a fifth aspect the invention provides a porous polymeric microfiltration or ultrafiltration membrane including a cross-linked hydrophilic polymer or copolymer.


Preferably, the cross-linked hydrophilic polymer or copolymer is integrated into a matrix of a porous microfiltration or ultrafiltration membrane also includes a non cross-linked and/or hydrophobic component.


Preferably, the membranes of the present invention are asymmetric membranes, which have a large pore face and a small pore face, and a pore size gradient which runs across the membrane cross section. The membranes may be flat sheet, or more preferably, hollow fibre membranes.


In another aspect, the invention provides a hydrophilic membrane prepared according to the present invention for use in the microfiltration and ultrafiltration of water and wastewater.


In another aspect, the invention provides a hydrophilic membrane prepared according to the present invention for use as an affinity membrane.


In another aspect, the invention provides a hydrophilic membrane prepared according to the present invention for use as protein adsorption.


In another aspect, the invention provides a hydrophilic membrane prepared according to the present invention for use in processes requiring bio-compatible functionalised membranes.


The term “hydrophilic” is relative and is used in the context of a refers to compound which when added to a base membrane component render the overall membrane more hydrophilic than if the membrane did not contain that compound.


BEST METHOD OF PERFORMING THE INVENTION

As mentioned above, the present invention can be carried out upon any polymeric microfiltration or ultrafiltration membrane which contains cross linkable moieties, monomers, oligomers, polymers and copolymers which are capable of cross linking to produce a hydrophilised membrane.


Membranes of the present invention possess the properties expected of hydrophilic membranes. However, unlike other hydrophilised membranes, they show an improved permeability and decreased pressure losses for filtration of any type, but in particular water filtration. This makes them suitable for applications such as filtration of surface water, ground water, secondary effluent and the like, or for use in membrane bioreactors.


Preferably, the cross linking is carried out by hydroxyl radicals generated from an aqueous solution of transition metal ions, in conjunction with hydrogen peroxide under acidic conditions. These conditions are sometimes described as producing Fenton's reagent.


Preferably the transition metal ions are iron II and/or iron II. Preferably, the acidic conditions are a pH of between about pH 2-6.


Any transition metal can be used, not just iron. Molybdenum, chromium, cobalt are also preferred. Any aqueous metal ion or complex that can easily be reduced/oxidised can be used as the catalyst system for the cleaning method of the present invention. Combinations of transition metal ions may also be used, and may be from a variety of sources, and can be supplemented with additional ions or species as necessary.


It has been found that a number of polymeric membranes, including PVdF, have a good resistance to hydroxyl radicals. This is surprising because polymeric membranes such as PVdF are not very stable with respect to ozone, and hydroxyl radicals are considered more powerful oxidising agents than ozone, for example in cleaning organics from fouled membranes. Without wishing to be bound by theory, it is possible that the reason for this may be due to the short lifetime of hydroxyl radicals.


In one preferred embodiment, the solution of hydroxyl radicals is prepared from an aqueous solution of M(n+) and/or M(n+1)+ (for example, an iron II and/or iron III system) in conjunction with hydrogen peroxide at a low pH. Starting with either M(n+) and/or M(n+1)+, an appropriate equilibrium between the two species will be reached. For instance, it is possible to start with either ferrous or ferric species, to get an identical catalyst system. Other practicalities may dictate one over the other, for instance, when the metal is iron, preferably iron II species are used to start the reaction because they tend to be more soluble than any corresponding iron III species. Thus, the possibility of undissolved iron III salts is reduced when starting from a solution of iron II.


The invention will be described with respect to iron II and iron III, but it will be understood to apply to any system where hydroxyl radicals are generated.


The general scheme for preparing hydroxyl radicals by the redox catalyst/peroxide/H+ system of the present invention is as shown below. The reaction of either iron II or iron III with hydrogen peroxide is possible, generating the complementary iron species.

Fe2++H2O2→Fe3++OH+HO
Fe3++H2O2→Fe2++OOH+H+

Overall:

2H2O2→H2O+HO31+−OOH


The hydroxyl radical is a strong oxidant, having a relative oxidation power over twice that of chlorine, and being second only to F in oxidative strength.


The individual redox catalyst/peroxide/H+ reagent components may be added to the cross linkable membrane together, or preferably separately, directly to the water which surrounds the fibre membranes.


Typically, a concentration less than 300 ppm of Fe can be used. Concentrations as low as 15-20 ppm Fe are efficacious, but the reaction time to achieve the desired degree of crosslinking is longer, for example, in excess of 24 hrs. Preferred concentrations are between 50-5000 ppm FeSO4, and more preferably 300-1200 ppm. Reaction times vary depending on the amount of cross linkable agent present and the concentration of hydroxyl radical available, as well as the temperature. Typical reaction times to achieve cross linking are from 0.5-24 hrs but more preferably 2-4 hrs.


Peroxide concentrations between 100-20000 ppm, more preferably between 400-10000 ppm and more preferably 1000-5000 ppm can be used. It is also preferable to have the ratio of Fe:H2O2 between 1:4 and 1:7.5, and more preferably between 1:5-1:25.


Preferably pH is in the range 2-6, more preferably 3-5.


A typical the redox catalyst/peroxide/H+ system of the present invention had a concentration of 0.12 wt % FeSO4 at pH2, and a peroxide concentration of between 5000 ppm and 9000 ppm.


The H2O2 can be added all at once, however, it is usually preferred if the H2O2 is added over the period of the reaction. For example, in the case of a 4000 ppm H2O2 concentration for a duration of 4 hours, H2O2 would be added at approximately 1000 ppm per hour.


Sodium hydrogen sulphate (NaHSO4) can be used to control the pH. Alternatively, any acid can be used, provided that the pH is in a suitable range. Citric acid or sulfuric acid can be used, either alone or buffered with a base, for example, NaOH, to get the desired pH. In one preferred embodiment, the pH is controlled by a sulfuric/caustic combination or sulfuric/sodium hydrogen sulfate combination. In highly preferred embodiments, pH is controlled by the use of citric acid, either alone or in combination with other species. Chloride ions can be present, e.g. in the form of FeCl3 or HCl.


The microfiltration/ultrafiltration membrane containing PVdF and uncross-linked PVP was immersed in an aqueous solution of ferric chloride/hydrogen peroxide and sodium hydrogensulfate and allowed to contact the stirred solution at room temperature for 4 hours before being removed and rinsed with distilled deionized water.


The washing was continued until no further material leached out in the wash. The crosslinkable component is preferably PVP. The crosslinkable component is preferably present in the membrane in an amount of 0.1-10 wt %, more preferably 2-7 wt %. It is highly preferable if the crosslinkable component is 0.1-10 wt % PVP, more preferably 2-7 wt % PVP.


As illustrated in the table and examples below, the only property of the membrane which is Substantially affected by the method of the present invention is permeability.


Thus, it is possible to improve the permeability (flux) of the membrane without sacrificing the pore size or mechanical integrity. This is achieved by cross-linking and also some leaching of the “cross-linkable component”, as explained earlier. The following examples illustrate the difference in permeability between the unmodified


The improved properties of membranes containing components cross-linked via hydroxyl radicals are illustrated in the following examples.


PVDF membranes containing a cross-linkable component were treated with solutions of 1 wt % H2O2 or Fenton's reagent. The Fenton's reagent had the concentration as follows:


0.12 wt % FeSO4.7H2O


0.1 wt % NaHSO4


0.9 wt % H2O2


The method for treating the membranes was as follows:






    • 1. Wash membranes in RO water (1 hr)

    • 2. Immerse membranes in treatment solution for specified time

    • 3. Rinse membranes in RO water (1 hr)

    • 4. Immerse membranes in 20 wt % glycerol (aqueous)

    • 5. Dry membranes at room temperature





The results are given in Table 1. Peroxide treatment to effect crosslinking increased permeability by about 20%, with only a slight reduction in break extension.


The use of Fenton's reagent as a crosslinking agent showed that after 1 hour, a 30% increase in permeability was obtained, with only a slight reduction in the break extension (from 179% to 169%), so the membrane was still highly flexible.


Longer treatment with Fenton's led to a loss in break extension, down to around 120%, which is nevertheless quite flexible. There was however a dramatic increase in the permeability—around a 200% increase in permeability over the untreated membrane.


There was otherwise no change in the morphology of the membranes resulting from either the Fenton's or peroxide cross-linking procedures.












TABLE 1






Unmodified
H2O2 Treated
Modified Membrane


Property
membrane
membrane
Fenton's reagent

























Treatment


1
hr
1
hr
1.3
hr
3
hr


Time


Outside
800
μm
800
μm
800
μm
800
μm
800
μm


Diameter


Inside
500
μm
500
μm
500
μm
500
μm
500
μm


Diameter


Pore size
<0.1
μm
<0.1
μm
<0.1
μm
<0.1
μm
<0.1
μm


(by SEM)


Permeability
192
lmh/bar
233
lmh/bar
252
lmh/bar
373
lmh/bar
583
lmh/bar


Bubble point
400-450
kPa
400-450
kPa
400-450
kPa
400-450
kPa
400-450
kPa












Break
179%
123%
169%
122%
120%


Extension


Wets with
Yes
Yes
Yes
Yes
Yes


water?










The following illustrates the cross-linking ability of hydroxyl radicals.


Samples of PVP K90 (10 wt %) and PVP K120 (9.3 wt %) were dissolved separately in RO water adjusted to pH 2 using NaHSO4. FeCl2 (0.04 wt %) was added and the solution was thoroughly mixed. H2O2 (0.32 wt %) was then added to the mixture, and a gel was immediately formed upon addition. This experiment was repeated with PVP K120 solutions ranging from 2.5-20 wt %, but replacing FeCl2 with FeSO4.7H2O. Insoluble gel was formed in each case with the exception of 2.5 wt % solution. It is believed that this concentration is too low as the sole component in a solution to form an insoluble gel. However the solution visibly increased in viscosity, suggesting some cross-linking is occurring.


Membranes made according to the present invention possess improved porosity and permeability properties, increasing the ability of the membrane to filter water. However, the membranes according to the present invention retain equivalent pore size, good pH (acid and base) and oxidation (Chlorine) resistant properties of the unmodified membranes in a filtration process.


The present invention provides improved permeability or porosity without sacrificing pore size or mechanical integrity.


While the invention has been described with reference to particular embodiments, it will be understood by those skilled in the art that the inventive concept disclosed herein is not limited only to those specific embodiments disclosed.

Claims
  • 1. A method of forming a hydrophilic polymeric microfiltration or ultrafiltration membrane comprising the steps of: preparing a dope comprising a polymeric material comprising polyvinylidene fluoride and a cross-linkable component;preparing a polymeric microfiltration or ultrafiltration membrane from the dope; andtreating the polymeric microfiltration or ultrafiltration membrane at a pH in the range of 2.0-9.0 with a hydroxyl radical generated by an aqueous solution comprising a transition metal catalyst, hydrogen sulfate, and hydrogen peroxide to cross-link said cross-linkable component.
  • 2. The method according to claim 1, wherein the transition metal catalyst is selected from the group consisting of iron, molybdenum, chromium and cobalt.
  • 3. The method according to claim 2, wherein the transition metal catalyst is iron.
  • 4. The method according to claim 3, wherein the transition metal catalyst is a mixture of iron II and iron III.
  • 5. The method according to claim 1, wherein the cross-linkable component is a hydrophilic cross-linkable component.
  • 6. The method according to claim 1, wherein the cross-linkable component is selected from the group consisting of monomers, oligomers, polymers and copolymers of one or more of the following: vinyl pyrrolidone, vinyl acetate, vinyl alcohol, vinyl methyl ether, vinyl ethyl ether, acrylic acid, methyl acrylate, ethyl acrylate, propyl acrylate, butyl acrylate, methyl methacrylate, ethyl methacrylate propyl methacrylate, butyl methacrylate and maleic anhydride.
  • 7. The method according to claim 1, wherein the cross-linkable component is selected from poly(vinyl pyrrolidone), poly(vinyl acetate) or copolymers of vinyl pyrrolidone and vinyl acetate.
  • 8. The method according to claim 1, wherein the cross-linkable component is added in an amount which produces only a minimal attenuation of the hydrophilicity/hydrophobicity balance of the membrane.
  • 9. The method according to claim 1, wherein the polymeric microfiltration or ultrafiltration membrane comprises a non-cross-linkable component.
  • 10. The method according to claim 9, wherein the non-cross-linkable component is a polymer or a copolymer of oxidation resistant material.
  • 11. The method according to claim 9 wherein the non-cross-linkable component is a polymer or a copolymer resistant to base attack.
  • 12. The method according to claim 9 wherein the non-cross-linkable component comprises a monomer selected from the group consisting of chlorotrifluoroethylene, vinyl fluoride, vinyl chloride, vinylidene fluoride/vinylidene chloride/hexafluoropropylene, ethylene-chlorotrifluoroethlyene, and tetrafluoroethylene.
  • 13. The method according to claim 1, wherein the hydrogen sulfate comprises sodium hydrogen_sulfate (NaHSO4).
  • 14. The method according to claim 1, wherein treating the polymeric microfiltration or ultrafiltration membrane with a hydroxyl radical generated by an aqueous solution comprising a transition metal catalyst and hydrogen peroxide comprises treating the membrane with a hydroxyl radical generated by an aqueous solution comprising ferric chloride, hydrogen peroxide and sodium hydrogensulfate.
  • 15. The method according to claim 1, wherein the aqueous solution further comprises sulphuric acid.
  • 16. The method according to claim 1, wherein further comprises citric acid.
  • 17. The method according to claim 1, further comprising applying ultraviolet radiation.
  • 18. The method according to claim 1, comprising at least one of soaking, filtering, or recirculating to cross-link the cross-linkable compound to the polymer matrix.
  • 19. The method according to claim 1, further comprising, after cross-linking, leaching an unbound amount of the cross-linkable component from the porous polymeric microfiltration or ultrafiltration membrane.
  • 20. The method according to claim 19, wherein leaching further comprises leaching with water.
  • 21. The method according to claim 19, wherein leaching further comprises leaching with a solvent compatible with the cross-linkable component.
  • 22. The method according to claim 19, wherein leaching further comprises leaching for a predetermined period of time.
  • 23. The method according to claim 19, wherein leaching further comprises leaching using a predetermined level of leachate.
Priority Claims (1)
Number Date Country Kind
2004906947 Dec 2004 AU national
PCT Information
Filing Document Filing Date Country Kind 371c Date
PCT/AU2005/001820 12/2/2005 WO 00 6/1/2007
Publishing Document Publishing Date Country Kind
WO2006/058384 6/8/2006 WO A
US Referenced Citations (291)
Number Name Date Kind
1994135 Horowitz Mar 1935 A
2658045 Schildknecht Nov 1953 A
3228876 Mahon Jan 1966 A
3275554 Wagenaar Sep 1966 A
3556305 Shorr Jan 1971 A
3625827 Wildi et al. Dec 1971 A
3654147 Levin et al. Apr 1972 A
3693406 Tobin, III Sep 1972 A
3708071 Crowley Jan 1973 A
3728256 Cooper Apr 1973 A
3744642 Scala et al. Jul 1973 A
3864289 Rendall Feb 1975 A
3876738 Marinaccio et al. Apr 1975 A
3968192 Hoffman, III et al. Jul 1976 A
3992301 Shippey et al. Nov 1976 A
3993816 Baudet et al. Nov 1976 A
4188817 Steigelmann Feb 1980 A
4192750 Elfes et al. Mar 1980 A
4193780 Cotton, Jr. et al. Mar 1980 A
4203848 Grandine, II May 1980 A
4218324 Hartmann et al. Aug 1980 A
4230583 Chiolle et al. Oct 1980 A
4247498 Castro Jan 1981 A
4248648 Kopp Feb 1981 A
4253936 Leysen et al. Mar 1981 A
4302336 Kawaguchi et al. Nov 1981 A
4340479 Pall Jul 1982 A
4353802 Hara et al. Oct 1982 A
4354443 Abrahamson Oct 1982 A
4384474 Kowalski May 1983 A
4385150 Miyake et al. May 1983 A
4388189 Kawaguchi et al. Jun 1983 A
4407975 Yamaguchi Oct 1983 A
4431545 Pall et al. Feb 1984 A
4451369 Sekino et al. May 1984 A
4511471 Müller Apr 1985 A
4519909 Castro May 1985 A
4540490 Shibata et al. Sep 1985 A
4547289 Okano et al. Oct 1985 A
4609465 Miller Sep 1986 A
4614109 Hofmann Sep 1986 A
4618533 Steuck Oct 1986 A
4623670 Mutoh et al. Nov 1986 A
4623690 Patzschke et al. Nov 1986 A
4629563 Wrasidlo Dec 1986 A
4632745 Giuffrida et al. Dec 1986 A
4636296 Kunz Jan 1987 A
4642182 Drori Feb 1987 A
4647377 Miura Mar 1987 A
4650586 Ellis, III Mar 1987 A
4656865 Callan Apr 1987 A
4660411 Reid Apr 1987 A
4670145 Edwards Jun 1987 A
4673507 Brown Jun 1987 A
4687561 Kunz Aug 1987 A
4688511 Gerlach et al. Aug 1987 A
4702836 Mutoh et al. Oct 1987 A
4702840 Degen et al. Oct 1987 A
4707266 Degen et al. Nov 1987 A
4708799 Gerlach et al. Nov 1987 A
4718270 Storr Jan 1988 A
4744240 Reichelt May 1988 A
4756875 Tajima et al. Jul 1988 A
4763612 Iwanami Aug 1988 A
4767539 Ford Aug 1988 A
4775471 Nagai et al. Oct 1988 A
4779448 Gogins Oct 1988 A
4784771 Wathen et al. Nov 1988 A
4793932 Ford et al. Dec 1988 A
4797187 Davis et al. Jan 1989 A
4797211 Ehrfeld et al. Jan 1989 A
4810384 Fabre Mar 1989 A
4812235 Seleman et al. Mar 1989 A
4816160 Ford et al. Mar 1989 A
4840227 Schmidt Jun 1989 A
4846970 Bertelsen et al. Jul 1989 A
4855163 Joffee et al. Aug 1989 A
4876006 Ohkubo et al. Oct 1989 A
4876012 Kopp et al. Oct 1989 A
4886601 Iwatsuka et al. Dec 1989 A
4888115 Marinaccio et al. Dec 1989 A
4904426 Lundgard et al. Feb 1990 A
4921610 Ford et al. May 1990 A
4931186 Ford et al. Jun 1990 A
4935143 Kopp et al. Jun 1990 A
4963304 Im et al. Oct 1990 A
4968733 Muller et al. Nov 1990 A
4999038 Lundberg Mar 1991 A
5005430 Kibler et al. Apr 1991 A
5015275 Beck et al. May 1991 A
5017292 DiLeo et al. May 1991 A
5019260 Gsell et al. May 1991 A
5024762 Ford et al. Jun 1991 A
5032282 Linder et al. Jul 1991 A
5043113 Kafchinski et al. Aug 1991 A
5049275 Gillberg-Laforce et al. Sep 1991 A
5066375 Parsi et al. Nov 1991 A
5066401 Müller et al. Nov 1991 A
5066402 Anselme et al. Nov 1991 A
5069065 Sprunt et al. Dec 1991 A
5075065 Effenberger et al. Dec 1991 A
5076925 Roesink et al. Dec 1991 A
5079272 Allegrezza et al. Jan 1992 A
5094750 Kopp et al. Mar 1992 A
5104535 Cote et al. Apr 1992 A
5104546 Filson et al. Apr 1992 A
H1045 Wilson May 1992 H
5135663 Newberth, III et al. Aug 1992 A
5137631 Eckman et al. Aug 1992 A
5137633 Wang Aug 1992 A
5138870 Lyssy Aug 1992 A
5147553 Waite Sep 1992 A
5151191 Sunaoka et al. Sep 1992 A
5151193 Grobe et al. Sep 1992 A
5158721 Allegrezza, Jr. et al. Oct 1992 A
5182019 Cote et al. Jan 1993 A
5192456 Ishida et al. Mar 1993 A
5192478 Caskey Mar 1993 A
5194149 Selbie et al. Mar 1993 A
5198116 Comstock et al. Mar 1993 A
5198162 Park et al. Mar 1993 A
5209852 Sunaoka et al. May 1993 A
5211823 Giuffrida et al. May 1993 A
5221478 Dhingra et al. Jun 1993 A
5227063 Langerak et al. Jul 1993 A
5248424 Cote et al. Sep 1993 A
5269084 Best et al. Dec 1993 A
5275766 Gadkaree et al. Jan 1994 A
5286324 Kawai et al. Feb 1994 A
5288324 Shaneyfelt Feb 1994 A
5297420 Gilliland et al. Mar 1994 A
5320760 Freund et al. Jun 1994 A
5353630 Soda et al. Oct 1994 A
5354587 Abayasekara Oct 1994 A
5361625 Ylvisaker Nov 1994 A
5364527 Zimmerman et al. Nov 1994 A
5376274 Muller et al. Dec 1994 A
5389260 Hemp et al. Feb 1995 A
5396019 Sartori et al. Mar 1995 A
5401401 Hickok et al. Mar 1995 A
5403479 Smith et al. Apr 1995 A
5403483 Hayashida et al. Apr 1995 A
5405528 Selbie et al. Apr 1995 A
5411663 Johnson May 1995 A
5417101 Weich May 1995 A
5419816 Sampson et al. May 1995 A
5451317 Ishida et al. Sep 1995 A
5470469 Eckman Nov 1995 A
5477731 Mouton Dec 1995 A
5479590 Lin Dec 1995 A
5480553 Yamamori et al. Jan 1996 A
5491023 Tsai et al. Feb 1996 A
5525220 Yagi et al. Jun 1996 A
5531848 Brinda et al. Jul 1996 A
5531900 Raghaven et al. Jul 1996 A
5543002 Brinda et al. Aug 1996 A
5543465 Bell et al. Aug 1996 A
5547575 Demmer et al. Aug 1996 A
5554283 Brinda et al. Sep 1996 A
5607593 Cote et al. Mar 1997 A
5629084 Moya May 1997 A
5639373 Mahendran et al. Jun 1997 A
5643455 Kopp et al. Jul 1997 A
5647988 Kawanishi et al. Jul 1997 A
5725769 Miller et al. Mar 1998 A
5747605 Breant et al. May 1998 A
D396046 Scheel et al. Jul 1998 S
5783083 Henshaw et al. Jul 1998 A
D396726 Sadr et al. Aug 1998 S
D400890 Gambardella Nov 1998 S
5871823 Anders et al. Feb 1999 A
5906742 Wang et al. May 1999 A
5910250 Mahendran et al. Jun 1999 A
5914039 Mahendran et al. Jun 1999 A
5918264 Drummond et al. Jun 1999 A
5942113 Morimura Aug 1999 A
5944997 Pedersen et al. Aug 1999 A
5958243 Lawrence et al. Sep 1999 A
5981614 Adiletta Nov 1999 A
5988400 Karachevtcev et al. Nov 1999 A
6024872 Mahendran Feb 2000 A
6039872 Wu et al. Mar 2000 A
6042677 Mahendran et al. Mar 2000 A
6045698 Cöté et al. Apr 2000 A
6045899 Wang et al. Apr 2000 A
6048454 Jenkins Apr 2000 A
6074718 Puglia et al. Jun 2000 A
6077435 Beck et al. Jun 2000 A
6083393 Wu et al. Jul 2000 A
6096213 Radovanovic et al. Aug 2000 A
6113794 Kumara et al. Sep 2000 A
6146747 Wang et al. Nov 2000 A
6156200 Zha et al. Dec 2000 A
6159373 Beck et al. Dec 2000 A
6193890 Pedersen et al. Feb 2001 B1
6202475 Selbie et al. Mar 2001 B1
6214231 Cote et al. Apr 2001 B1
6221247 Nemser et al. Apr 2001 B1
6245239 Cote et al. Jun 2001 B1
6254773 Biltoft Jul 2001 B1
6264839 Mohr et al. Jul 2001 B1
6277512 Hamrock et al. Aug 2001 B1
6280626 Miyashita et al. Aug 2001 B1
6284135 Ookata Sep 2001 B1
6294039 Mahendran et al. Sep 2001 B1
6299773 Takamura et al. Oct 2001 B1
6315895 Summerton et al. Nov 2001 B1
6322703 Taniguchi et al. Nov 2001 B1
6325928 Pedersen et al. Dec 2001 B1
6337018 Mickols Jan 2002 B1
RE37549 Mahendran et al. Feb 2002 E
6354444 Mahendran Mar 2002 B1
6355730 Kozawa et al. Mar 2002 B1
6375848 Cote et al. Apr 2002 B1
6423784 Hamrock et al. Jul 2002 B1
6440303 Spriegel Aug 2002 B2
D462699 Johnson et al. Sep 2002 S
6448062 Huth et al. Sep 2002 B1
6465748 Yamanashi et al. Oct 2002 B2
6491165 Kuske Dec 2002 B2
6495041 Taniguchi et al. Dec 2002 B2
6524481 Zha et al. Feb 2003 B2
6550747 Rabie et al. Apr 2003 B2
6555005 Zha et al. Apr 2003 B1
6595167 Kaesgen Jul 2003 B2
6596167 Ji et al. Jul 2003 B2
D478913 Johnson et al. Aug 2003 S
6620319 Behmann et al. Sep 2003 B2
6635104 Komkova et al. Oct 2003 B2
6635179 Summerton et al. Oct 2003 B1
6641733 Zha et al. Nov 2003 B2
6645374 Cote et al. Nov 2003 B2
6656356 Gungerich et al. Dec 2003 B2
6682652 Mahendran et al. Jan 2004 B2
6685832 Mahendran et al. Feb 2004 B2
6705465 Ling Mar 2004 B2
6721529 Chen et al. Apr 2004 B2
6723758 Stone et al. Apr 2004 B2
6727305 Pavez Aranguiz Apr 2004 B1
6761013 Tippey Jul 2004 B2
6770202 Kidd et al. Aug 2004 B1
6783008 Zha et al. Aug 2004 B2
6790912 Blong Sep 2004 B2
6793820 McCray et al. Sep 2004 B1
6811696 Wang et al. Nov 2004 B2
6821420 Zha et al. Nov 2004 B2
6830782 Kanazawa Dec 2004 B2
6851259 Simburger Feb 2005 B2
6861466 Dadalas et al. Mar 2005 B2
6872305 Johnson et al. Mar 2005 B2
6884350 Muller Apr 2005 B2
6884375 Wang et al. Apr 2005 B2
6890435 Ji et al. May 2005 B2
6890645 Disse et al. May 2005 B2
6893568 Janson et al. May 2005 B1
6965033 Jiang Nov 2005 B2
6969465 Zha et al. Nov 2005 B2
6974554 Cox et al. Dec 2005 B2
6994867 Hossainy et al. Feb 2006 B1
7041728 Zipplies et al. May 2006 B2
7070909 Japp et al. Jul 2006 B2
7128768 Liu Oct 2006 B2
7226541 Muller et al. Jun 2007 B2
7300022 Muller Nov 2007 B2
7395646 Salman Jul 2008 B2
7404896 Muller Jul 2008 B2
7449112 Lee et al. Nov 2008 B2
7459085 Koguma et al. Dec 2008 B2
7537718 Mezhirov et al. May 2009 B2
7648034 Charkoudian et al. Jan 2010 B2
20020148767 Johnson et al. Oct 2002 A1
20030065302 Kuroda Apr 2003 A1
20030178365 Zha et al. Sep 2003 A1
20030226797 Phelps Dec 2003 A1
20040084369 Zha et al. May 2004 A1
20040085300 Matusis May 2004 A1
20040092901 Reeca May 2004 A1
20040145076 Zha et al. Jul 2004 A1
20040167490 Nelson Aug 2004 A1
20040167493 Jarpenberg Aug 2004 A1
20040168947 McDonald Sep 2004 A1
20040172002 Nelson Sep 2004 A1
20040176735 Snell Sep 2004 A1
20040195172 Yeh et al. Oct 2004 A1
20040217053 Zha et al. Nov 2004 A1
20050015052 Klippen Jan 2005 A1
20050032982 Muller Feb 2005 A1
20050098494 Mullette et al. May 2005 A1
20060157404 Mullette et al. Jul 2006 A1
20060178480 Tada et al. Aug 2006 A1
20070007197 Mahendran et al. Jan 2007 A1
Foreign Referenced Citations (119)
Number Date Country
2005312347 Mar 2010 AU
1135188 Nov 1996 CN
1552507 Dec 2004 CN
3904544 Aug 1990 DE
4007383 Sep 1991 DE
4117281 Jan 1992 DE
4113420 Oct 1992 DE
4117422 Nov 1992 DE
19503060 Aug 1996 DE
29906389 Jun 1999 DE
012557 Feb 1983 EP
050447 Oct 1985 EP
229019 Jul 1987 EP
250337 Dec 1987 EP
261734 Mar 1988 EP
407900 Jan 1991 EP
419396 Mar 1991 EP
463627 Jan 1992 EP
492942 Jul 1992 EP
509663 Oct 1992 EP
550798 Jul 1993 EP
395133 Feb 1995 EP
492446 Nov 1995 EP
430082 Jun 1996 EP
581168 Oct 1996 EP
763758 Mar 1997 EP
911073 Apr 1999 EP
920904 Jun 1999 EP
1034835 Sep 2000 EP
1052012 Nov 2000 EP
1236503 Aug 2004 EP
2620712 Mar 1989 FR
2674448 Oct 1992 FR
2850297 Jul 2004 FR
702911 Jan 1954 GB
2253572 Sep 1992 GB
2390042 Dec 2003 GB
55-129155 Jun 1980 JP
58-088007 May 1983 JP
60-260628 Dec 1985 JP
61-097006 May 1986 JP
61-107905 May 1986 JP
61-192309 Aug 1986 JP
61-257203 Nov 1986 JP
61-263605 Nov 1986 JP
62-004408 Jan 1987 JP
62-068828 Mar 1987 JP
62-114609 May 1987 JP
62-140607 Jun 1987 JP
62-179540 Aug 1987 JP
62-250908 Oct 1987 JP
63-097634 Apr 1988 JP
S63-38884 Oct 1988 JP
06-027215 Mar 1989 JP
10-75542 Mar 1989 JP
01-307409 Dec 1989 JP
02-031200 Feb 1990 JP
02-144132 Jun 1990 JP
02-164423 Jun 1990 JP
02-284035 Nov 1990 JP
03-018373 Jan 1991 JP
03-110445 May 1991 JP
04-187224 Jul 1992 JP
04-250898 Sep 1992 JP
04-265128 Sep 1992 JP
04-310223 Nov 1992 JP
05-023557 Feb 1993 JP
05-096136 Apr 1993 JP
05131124 May 1993 JP
05-157654 Jun 1993 JP
05-285348 Nov 1993 JP
06-071120 Mar 1994 JP
06-114240 Apr 1994 JP
06-218237 Aug 1994 JP
06-285496 Oct 1994 JP
06-343837 Dec 1994 JP
07-000770 Jan 1995 JP
07-024272 Jan 1995 JP
07-155758 Jun 1995 JP
07-185268 Jul 1995 JP
07-185271 Jul 1995 JP
07-275665 Oct 1995 JP
08-010585 Jan 1996 JP
09-141063 Jun 1997 JP
09-220569 Aug 1997 JP
09-324067 Dec 1997 JP
10-156149 Jun 1998 JP
11-165200 Jun 1999 JP
11-302438 Nov 1999 JP
2000-342932 Dec 2002 JP
2004230280 Aug 2004 JP
2005154551 Jun 2005 JP
2002031017 Jul 2002 KR
WO 88-06200 Aug 1988 WO
WO 90-00434 Jan 1990 WO
9117204 Nov 1991 WO
WO 93-02779 Feb 1993 WO
WO 93-15827 Aug 1993 WO
WO 95-34424 Dec 1995 WO
WO 96-07470 Mar 1996 WO
WO 96-41676 Dec 1996 WO
WO 98-22204 May 1998 WO
WO 98-25694 Jun 1998 WO
WO 98-28066 Jul 1998 WO
WO 99-01207 Jan 1999 WO
WO0043115 Jul 2000 WO
WO0238256 May 2002 WO
02087734 Nov 2002 WO
WO 03068374 Aug 2003 WO
WO 03080228 Oct 2003 WO
03095078 Nov 2003 WO
WO 2004078327 Sep 2004 WO
WO 2004094049 Nov 2004 WO
2005005028 Jan 2005 WO
WO2005002712 Jan 2005 WO
WO 2005030916 Apr 2005 WO
2006002479 Jan 2006 WO
WO 2006058384 Jun 2006 WO
2006058394 Aug 2006 WO
Related Publications (1)
Number Date Country
20090230053 A1 Sep 2009 US